EyePoint Pharmaceuticals, Inc.

Informe acción NasdaqGM:EYPT

Capitalización de mercado: US$627.9m

EyePoint Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de EyePoint Pharmaceuticals han disminuido a una tasa media anual de -16.4%, mientras que en la industria Pharmaceuticals los beneficios crecieron en un 1.2% anualmente. Los ingresos han ido creciendo a una tasa media de 14.8% al año.

Información clave

-16.4%

Tasa de crecimiento de los beneficios

20.7%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals 6.0%
Tasa de crecimiento de los ingresos14.8%
Rentabilidad financiera-47.3%
Margen neto-226.6%
Última actualización de beneficios30 Sep 2024

Actualizaciones de resultados anteriores recientes

Recent updates

EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity

Nov 14

Revenues Not Telling The Story For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Shares Rise 52%

Oct 29
Revenues Not Telling The Story For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Shares Rise 52%

EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Intrinsic Value Is Potentially 38% Above Its Share Price

Sep 13
EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Intrinsic Value Is Potentially 38% Above Its Share Price

EyePoint Pharmaceuticals - After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)

Aug 29

These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat

Aug 15
These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 09
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Some Confidence Is Lacking In EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) As Shares Slide 27%

Jun 19
Some Confidence Is Lacking In EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) As Shares Slide 27%

EyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)

May 06

More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%

Mar 31
More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%

EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time

Feb 20

Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%

Feb 05
Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%

Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?

Jan 29
Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?

Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 194% But Growth Is Lacking

Dec 18
Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 194% But Growth Is Lacking

These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat

Dec 13
These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat

Calculating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

May 14
Calculating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 84% But Growth Is Lacking

Apr 17
Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 84% But Growth Is Lacking

EyePoint Pharmaceuticals: Key Player In The Long-Acting Wet AMD Space

Aug 30

Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?

Jul 16
Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?

EyePoint Pharma announces 12-month phase 1 data for its treatment for eye disorder wAMD

Jul 15

Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?

Mar 06
Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?

Desglose de ingresos y gastos

Cómo gana y gasta dinero EyePoint Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

NasdaqGM:EYPT Ingresos, gastos y beneficios (USD Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
30 Sep 2446-104510
30 Jun 2450-874921
31 Mar 2450-79500
31 Dec 2346-71510
30 Sep 2343-100550
30 Jun 2337-1065927
31 Mar 2340-102600
31 Dec 2241-102600
30 Sep 2242-78640
30 Jun 2241-77620
31 Mar 2239-67580
31 Dec 2137-58540
30 Sep 2133-54480
30 Jun 2139-42450
31 Mar 2134-44440
31 Dec 2034-45460
30 Sep 2036-40460
30 Jun 2023-52470
31 Mar 2026-51480
31 Dec 1920-57480
30 Sep 1914-58450
30 Jun 1912-75410
31 Mar 196-98350
31 Dec 185-86250
30 Sep 183-80180
30 Jun 183-53130
31 Mar 183-25100
31 Dec 173-23100
30 Sep 178-1790
30 Jun 178-18110
31 Mar 177-19100
31 Dec 167-19100
30 Sep 161-24100
30 Jun 162-2290
31 Mar 162-2090
31 Dec 152-2080
30 Sep 152-1980
30 Jun 1527680
31 Mar 1526880
31 Dec 14281080
30 Sep 14281170
30 Jun 143-1370
31 Mar 144-1380
31 Dec 132-1470

Ingresos de calidad: EYPT actualmente no es rentable.

Margen de beneficios creciente: EYPT actualmente no es rentable.


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: EYPT no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 16.4% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de EYPT en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: EYPT no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Pharmaceuticals (54.6%).


Rentabilidad financiera

Alta ROE: EYPT tiene una rentabilidad financiera negativa (-47.35%), ya que actualmente no es rentable.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado